Featured News Coverage
Our breakthrough findings on B. infantis and its impacts on infant health have been addressed in notable publications around the world.
Now our drug candidate INF108 is of great interest to the neonatology community.
Featured Press
FDA Grants Orphan Drug & Rare Pediatric Disease Designations to Infinant Health for NEC
Next step is to conduct a Phase 1 safety trial on drug candidate INF108, followed by a Phase 2/3 efficacy trial. If success is achieved in clinical trials, ODD also allows for a waiver of the BLA filing fee (a >$4M savings) and if FDA approves the product for marketing, the potential for market exclusivity.
Infinant Health Appoints new Team Members to assist with Drug Development
Infinant Health announces additions to their advisory team: Dr. Katharine Knobil and Dr. David Pompliano. Additionally, Judy Gawlik Brown has joined the board, representing Manna Tree Partners, to help prepare the company's expansion into pharma.
Infinant Health Announces Submission of Orphan Drug Designation
Infinant Health announced it has filed an application with the U.S. Food and Drug Administration (FDA) to receive Orphan Drug Designation (ODD) for its drug candidate INF108 for the prevention of necrotizing enterocolitis in pre-term infants.
Infinant Health Hosts Screening of the Invisible Extinction and Q&A with Film's Scientists
Ininfant Health hosted an exclusive screening of the award-winning documentary, The Invisible Extinction. In the film, scientists Dr. Martin Blaser and Dr. Maria Gloria Dominguez-Bello trace the disappearance of microbiomes that help digestion beginning in infancy and keep bodies healthy.
Last Participant Enrolled in Study of Infant Microbiome and Immune Health
Prospective study designed to assess the immunological effect of a specific B. infantis strain on the incidence of atopic dermatitis, one of the most prevalent pediatric allergic diseases.
Infinant Health Announces Mike Johnson as Chief Executive Officer
Former Infinant Health, Inc Board Member Mike Johnson will lead the company as it continues to spearhead innovative advancements in science surrounding infant health
Infinant Health and Connected World Without Disease Accelerator (CWWDA) Announce Global Strategic Partnership
Together, CWWDA and Infinant Health will demonstrate the power of promoting health care from birth, rather than disease care later.
Infinant Health Announces Collaboration with Janssen to Study the Impact of B. infantis EVC001 in the Reduction of Atopic Dermatitis
Study aims to investigate whether infant probiotic Evivo can reduce development of early childhood atopic dermatitis.
New study reports reductions in diaper rash and colic as well as improvement in sleep in infants following supplementation with the specific gut bacterium activated B. infantis EVC001
Researchers in Beneficial Microbes reported that three common infant health issues associated with Newborn Gut Deficiency were reduced or eliminated altogether within days of introducing a key beneficial gut bacterium.
Adding a Single Key Gut Bacterium, B. infantis EVC001 to Human Milk Feeding Protocols May Help in the Managed Care of Very Low Birth Weight Infants
Study Published in Journal of Pediatrics Discusses Potential for Improved Clinical Care Associated with Administration of B. infantis EVC001 in Very Low Birth Weight Infants
Around The Industry
Mother Jones
What if the Secret to Preventing Several Common Diseases Is Hiding in Our Babies’ Poop?
Baby Gaga
Researchers Ring The Alarm On Infant Gut Deficiency & How it Affects Development
KTLA
Food Allergies in Children on the Rise, What Parents Need to Know With Dr. Tanya Altmann
Science Trends
B. infantis EVC001 Reduces the Genes in Bacteria That Cause Antibiotic Resistance By 90 Percent
